Toll Free: 1-888-928-9744

Bronchiectasis - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Bronchiectasis Pipeline Review, H2 2015


Global Markets Direct’s, ‘Bronchiectasis Pipeline Review, H2 2015’, provides an overview of the Bronchiectasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Bronchiectasis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Bronchiectasis Overview 7
Therapeutics Development 8
Pipeline Products for Bronchiectasis – Overview 8
Bronchiectasis – Therapeutics under Development by Companies 9
Bronchiectasis – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bronchiectasis – Products under Development by Companies 13
Bronchiectasis – Companies Involved in Therapeutics Development 14
Alitair Pharmaceuticals, Inc. 14
Bayer AG 15
Grifols, S.A. 16
Kamada Ltd. 17
Nostrum Pharmaceuticals, LLC 18
Pulmatrix, Inc. 19
Recipharm AB 20
Savara Inc. 21
Serendex Pharmaceuticals A/S 22
Therabron Therapeutics, Inc. 23
Vertex Pharmaceuticals Incorporated 24
Bronchiectasis – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles alpha-1 proteinase inhibitor (human) second generation – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ALT-09 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ARD-3150 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BAY-858501 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CG-1011 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ciprofloxacin – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
dapsone – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
doxofylline – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
erdosteine – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Leukotriene B4 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
levofloxacin – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
molgramostim – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PB-01 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
vancomycin hydrochloride – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VX-371 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Bronchiectasis – Recent Pipeline Updates 60
Bronchiectasis – Dormant Projects 67
Bronchiectasis – Discontinued Products 68
Bronchiectasis – Product Development Milestones 69
Featured News & Press Releases 69
Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 69
Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 70
Sep 02, 2015: Pulmatrix Issued New Composition of Matter Patent Covering iSPERSE Technology 70
Aug 09, 2015: Serendex to initiate first phase II clinical trial 71
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced 72
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases 72
May 10, 2015: Positive topline data from Serendex phase I clinical trial 73
Feb 27, 2015: Serendex submits phase I application 74
Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia 74
Nov 24, 2014: FDA Grants QIDP Designation to Bayer’s Ciprofloxacin Dry Powder for Inhalation 75

Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77
List of Tables

Number of Products under Development for Bronchiectasis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Bronchiectasis – Pipeline by Alitair Pharmaceuticals, Inc., H2 2015 14
Bronchiectasis – Pipeline by Bayer AG, H2 2015 15
Bronchiectasis – Pipeline by Grifols, S.A., H2 2015 16
Bronchiectasis – Pipeline by Kamada Ltd., H2 2015 17
Bronchiectasis – Pipeline by Nostrum Pharmaceuticals, LLC, H2 2015 18
Bronchiectasis – Pipeline by Pulmatrix, Inc., H2 2015 19
Bronchiectasis – Pipeline by Recipharm AB, H2 2015 20
Bronchiectasis – Pipeline by Savara Inc., H2 2015 21
Bronchiectasis – Pipeline by Serendex Pharmaceuticals A/S, H2 2015 22
Bronchiectasis – Pipeline by Therabron Therapeutics, Inc., H2 2015 23
Bronchiectasis – Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Bronchiectasis Therapeutics – Recent Pipeline Updates, H2 2015 60
Bronchiectasis – Dormant Projects, H2 2015 67
Bronchiectasis – Discontinued Products, H2 2015 68 

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.